Quick Facts

• Primary Use: Management of pulmonary arterial hypertension (PAH).
• Benefit in Adults: May improve exercise ability and help decrease clinical worsening associated with PAH.
• Benefit in Children (3 years and older): May help improve pulmonary vascular resistance (PVR).

Bopaho (Bosentan) is a prescription medication authorized for the management of pulmonary arterial hypertension (PAH) in adults and pediatric patients aged 3 years and older. PAH is a condition characterized by high blood pressure in the arteries that carry blood from the heart to the lungs.

In adults, this medication is used to help improve a patient's capacity for physical activity and to contribute to a reduction in the rate of disease progression, often in those with WHO Functional Class II-IV symptoms. For pediatric patients aged 3 years and older, the medication may help facilitate an improvement in pulmonary vascular resistance, which is an expected measure of better exercise ability.

Treatment with this medication is typically administered as part of a comprehensive strategy and should always be initiated under the guidance of a qualified healthcare provider.

Official Eligibility and Contraindications

Bopaho (Bosentan) is approved for use in patients with pulmonary arterial hypertension (PAH) to improve exercise ability and reduce clinical worsening. Its use is subject to strict rules and is contraindicated in several specific populations, based on regulatory labeling.

Category	Eligibility Status (Regulatory)
Pregnancy	Contraindicated (likely to cause major birth defects). Females of reproductive potential must use two reliable forms of contraception during treatment and for one month after the last dose, and must have monthly pregnancy tests.
Concomitant Use	Contraindicated with Cyclosporine A and Glyburide due to increased risks of drug concentration or liver enzyme elevation.
Hypersensitivity	Contraindicated in patients with a known hypersensitivity to the medicine or its components.
Liver Function	Should not be initiated in patients with elevated liver aminotransferases (>3 times the upper limit of normal). Avoid use in moderate or severe liver impairment.
Lactation	Not recommended; women should be advised against breastfeeding.

This medicine is available only through a restricted distribution program to manage the risks of fetal harm and liver injury.

Interactions with other medicines and products

Bopaho's interaction profile is primarily defined by its effects on drug metabolism and transport, as documented in official regulatory labeling.

Formal Contraindications and Restrictions The co-administration of Bopaho with Cyclosporine A and Glyburide is formally contraindicated by health authorities due to significant risks related to increased exposure and liver enzyme elevation, respectively.

Pharmacokinetic Interaction Patterns Bopaho acts as a documented inducer of metabolic enzymes CYP2C9 and CYP3A4, as well as the transporter P-glycoprotein. This action is the basis for reducing the systemic exposure of many co-administered medicinal products.

Interacting Substance/Class	Official Interaction Outcome	Timing/Procedural Constraint
Hormonal Contraceptives	Decreased exposure; reduced effectiveness.	Use two reliable contraceptive methods simultaneously.
Statins (e.g., Simvastatin)	Decreased plasma levels; reduced efficacy.	Dosing adjustments may be considered.
Ritonavir (HIV Regimens)	Increased Bopaho exposure.	Mandatory discontinuation for at least 36 hours prior to initiation.
Hepatic Impairment	Significant increase in Bopaho exposure.	Use generally avoided in moderate or severe impairment.

This regulatory structure details the required constraints and prohibitions necessary to manage the established pharmacokinetic interactions.

Bopaho (Bosentan) acts exclusively at the biological level by interfering with the Endothelin signaling system, which regulates blood vessel diameter and cell growth within the pulmonary vasculature.

Non-Selective Blockade of ET A and ET B Receptors

The mechanism is initiated by Bopaho acting as a non-selective competitive antagonist on two receptor subtypes: ET A and ET B. This blockade prevents the binding of Endothelin-1 ( ET-1), a potent endogenous constrictor, thereby inhibiting the molecular signal that drives both acute vasoconstriction and long-term abnormal cell proliferation within the pulmonary arteries.

Vasodilation and Vascular Remodeling Reversal

This molecular blockade translates directly into two primary physiological effects: the immediate relaxation of pulmonary vascular smooth muscle, resulting in vasodilation, and the inhibition of cellular growth. This dual action facilitates the sustained reduction of pulmonary vascular resistance (PVR) and contributes to the reversal of structural thickening of the arterial walls, leading to a decreased mechanical afterload on the right ventricle.

How to Use Bopaho

Bopaho (Bosentan) is intended for oral administration only and is utilized as a long-term continuous therapy to manage chronic pulmonary conditions. The medication is supplied as either a film-coated tablet or a dispersible tablet, with distinct preparation steps based on the form.

Dosing Regimen and Schedule

Treatment is initiated with a dose titration phase. For adults, the standard protocol is to start at 62.5 mg twice daily for a period of four weeks. Following this introductory phase, the dose is increased to the maintenance level of 125 mg twice daily. The medication is taken consistently twice a day, once in the morning and once in the evening, and can be administered with or without food.

Administration Context and Special Rules

Procedural constraints dictate that film-coated tablets must be swallowed whole, whereas the dispersible tablet must be suspended in a small amount of water immediately before intake.

For pediatric patients aged 3 years and older, dosing is calculated based on body weight up to the adult maximum dose. Furthermore, initiation of therapy and any dose adjustments must be managed by a physician specialized in the treatment of pulmonary arterial hypertension. If a dose is missed, the protocol is to take only the next scheduled dose at its regular time and not take a double dose to compensate. This structured protocol ensures adherence to the established method for using Bopaho.

Research Evidence / Overview of Studies for Bopaho (Bosentan)

Evidence from Trials in Adults with Pulmonary Arterial Hypertension (PAH)

Research into Bopaho for adults with Pulmonary Arterial Hypertension (PAH) has primarily involved short-term, placebo-controlled randomized clinical trials (RCTs). These types of studies explore specific questions by comparing the medicine against an inactive substance (placebo) over a short, defined period. In these trials, researchers examined important outcomes reflecting daily functioning or activity level, measured using functional capacity metrics, such as the 6-minute walk distance (6MWD). They also studied the time to clinical worsening, which is a combined measure that monitors disease progression.

Studies exploring Bopaho monitored physiological strain by evaluating internal measurements known as hemodynamic parameters. Studies reported data showing patterns related to measured differences in functional exercise capacity and in the rate of clinical worsening events when compared to patients who received the placebo. One limitation noted is that the follow-up durations were limited in the initial controlled trials, typically lasting less than seven months, meaning long-term outcomes are less directly established by these initial trials.

Research Findings for Pediatric Patients

Bopaho was studied for use in children aged 3 years and older, relying on a combination of small prospective trials and observational cohorts. The main outcomes monitored were changes in Pulmonary Vascular Resistance Index (PVRi). The studies reported how these internal pressure measurements evolved in the observed populations. For this group, conclusions were drawn by comparing the observed outcomes to the established adult research base. The certainty remains low for specific functional outcomes, and the sample sizes were modest, reflecting the challenges of studying a rare condition in children.

Areas of Uncertainty and Evidence Gaps in the Research

Certain areas of uncertainty remain in the Bopaho evidence landscape. Research for some populations, particularly children and adults with milder disease, relies on the evaluation of surrogate markers like PVRi, and not always on the direct patient-reported outcomes describing perceived discomfort. Additionally, comparative evidence is lacking to directly show how Bopaho compares against all other specialized PAH therapies in head-to-head RCTs. The evidence quality varies across studies, and findings describe group patterns, so research does not determine whether an individual will respond similarly.

Key Studies & References Endothelin receptor antagonists for pulmonary arterial hypertension: a systematic review and meta-analysis

Common questions about Bopaho (FAQ)

---

Q: Is Bopaho the same kind of medicine as [similar drug name]?

A: According to the official product information, Bopaho contains the active substance Bosentan and is classified as an Endothelin Receptor Antagonist (ERA). This means it belongs to a specific pharmacological group used to manage conditions associated with high pressure in the pulmonary arteries. Other medications that may seem similar could belong to entirely different drug classes.

Q: Can women who are planning to become pregnant use Bopaho?

A: Official regulatory documents state that Bopaho is contraindicated for patients who are pregnant or are planning to become pregnant. Due to the documented risk of fetal harm, regulatory information states that females of reproductive potential must use two reliable forms of contraception during treatment and for one month after the last dose.

Q: Does taking Bopaho affect the results of common lab tests?

A: Bopaho is associated with effects on certain laboratory values, which necessitates regular monitoring. Official documents describe that the medicine can cause decreases in both hemoglobin and hematocrit levels, as well as elevations in liver aminotransferases.

Q: What kind of monitoring (e.g., blood tests) is sometimes done while taking Bopaho?

A: Monitoring includes regular blood tests, such as required monthly measurement of liver aminotransferases (ALT/AST) to measure liver aminotransferase levels. Checks of hemoglobin and hematocrit levels are also necessary at specific intervals after treatment starts, and then every three months thereafter.

Q: Does Bopaho interact with common pain relievers like ibuprofen or acetaminophen?

A: Bopaho is known to act as an enzyme inducer in the body, which can speed up the metabolism of other substances. Official documents state that Bopaho may reduce the blood levels and expected effects of certain medicines, including some nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Why is it important to share my full medical history before starting Bopaho?

A: Official guidance describes sharing a full medical history as important for safety. Sharing a full medical history allows for the review of all known contraindications (conditions where the drug should not be used), assessment of potential risk factors for adverse reactions like anemia, and review of all concomitant medications for potential interactions.

Q: Does Bopaho interact with common herbal supplements like St. John's Wort?

A: Official guidance indicates that patients should inform their healthcare provider about all herbal products and supplements they are using. This is necessary because Bopaho is a known enzyme inducer that can change the body's concentration of other substances, potentially leading to reduced effectiveness of other medicines.

Q: How quickly does Bopaho start to show its expected effect?

A: Studies examining the effects of Bopaho measured an improvement in functional capacity, such as the 6-minute walk distance. The data indicates this improvement was typically apparent after 1 month of treatment and was fully developed by about 2 months.

Q: Is there a certain time of day that Bopaho is generally described to be taken?

A: Official documents describe that the medicine is intended to be taken consistently twice a day to maintain stable drug levels. This schedule is typically described as being taken once in the morning and once in the evening.

Q: Do people typically stop Bopaho suddenly, or is a slow change usually described?

A: Official protocols for stopping the medicine often suggest a gradual change, such as a temporary dose reduction over several days. Official protocol suggests this approach, as stopping the medicine abruptly may cause a worsening of the underlying condition.

Q: What should I do if I think I'm having a rare side effect from Bopaho?

A: Official patient information states that patients should contact their doctor or healthcare provider immediately if they experience any new or unusual symptoms. This allows a healthcare professional to assess the situation quickly and determine the appropriate next steps.

Q: Is Bopaho linked to any specific warnings or precautions in official government documents?

A: Yes, official regulatory documents contain several warnings, including the two Boxed Warnings for potential Hepatotoxicity (liver injury) and Embryo-Fetal Toxicity (birth defects). Other documented precautions include monitoring for fluid retention and the potential for a decrease in sperm count.

Q: Does the efficacy of Bopaho change over time with continued use?

A: Evidence from the initial placebo-controlled trials suggests that the improvement in exercise capacity seen within the first two months was maintained for the duration of those short-term studies, which lasted up to approximately seven months.

Q: Can people with liver function issues use Bopaho?

A: The official product label states that the use of Bopaho is generally avoided if liver enzyme levels are significantly elevated before starting treatment. If liver enzyme elevations occur during therapy, the official protocol includes temporary interruption or reduction of the medicine.

Q: What is the average duration of treatment with Bopaho described in studies?

A: Bopaho is generally prescribed as a long-term continuous therapy for the management of chronic pulmonary conditions. While the initial controlled trials had follow-up periods lasting less than seven months, the purpose of the medicine is for sustained management.

Q: Is Bopaho available in generic form?

A: Yes, the active ingredient in Bopaho, known as Bosentan, has been approved by the FDA as a generic product. This means that generic versions are available from multiple manufacturers.

Q: Can Bopaho affect my ability to focus or concentrate?

A: Official documents list headache as a common adverse reaction in patients. If a patient experiences changes in focus, concentration, or any other new or worsening effects, official guidance indicates that they should consult their healthcare provider.

Q: What are the signs that Bopaho is working as intended?

A: In clinical studies, efficacy was primarily measured by objective outcomes reflecting daily functioning. These outcomes included an improvement in exercise ability, which is often measured by the 6-minute walk distance, and a reduced rate of clinical worsening events.

Q: Can people with a history of kidney problems use Bopaho?

A: Official regulatory documents list strict contraindications regarding liver function and pregnancy. While kidney function is not listed as a formal contraindication, healthcare providers assess the use of the medicine based on a patient's overall health and the presence of any other pre-existing conditions.

Q: Do studies suggest that Bopaho works differently for men versus women?

A: While there are strict safety restrictions specific to females of reproductive potential (due to the risk of birth defects), official documents do not highlight any significant differences in how the medicine works (efficacy) based on sex in adult patients.

Q: Are there any documented cases of Bopaho overdose?

A: Clinical studies have examined high single doses and high daily doses in both healthy volunteers and patients. The most common effect observed at these high-dose levels was headache of mild to moderate intensity.

Q: Do patients typically report needing to adjust their lifestyle while on Bopaho?

A: Official guidelines describe several critical adjustments, including the required use of two reliable forms of non-hormonal contraception for females of reproductive potential. Additionally, patients must avoid the co-administration of certain medications that are explicitly listed as contraindications.

Q: What information should I have ready before discussing Bopaho with my healthcare provider?

A: Official guidance indicates that patients should be prepared to discuss all prescription and nonprescription medicines, vitamins, supplements, and herbal products they are currently using. It is also important to discuss any existing health problems, such as liver or heart failure and anemia, and any plans regarding pregnancy or breastfeeding.

Q: Why is the dispersible tablet described as a differentiating factor for specific patient groups?

A: The availability of a dispersible tablet formulation is a differentiating factor because it is designed for use in patients who are unable to swallow the film-coated tablets whole. This is particularly relevant for certain patient groups, such as children aged three years and older.

Q: Is Bopaho considered a medication that requires a special prescription or monitoring?

A: Yes, Bopaho is a prescription-only drug that is available only through a restricted distribution program (REMS) due to the risks of liver injury and birth defects. This program requires mandatory enrollment and adherence to a strict monitoring schedule, including regular blood tests.

Storage Requirements

Bopaho (Bosentan) must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original packaging, and patients are formally advised not to swallow the desiccant if present in the bottle.

For the dispersible tablets, if a piece is divided, it has a stability limit and must be returned to the opened blister pack for storage and used within 7 days.

Child Safety and Disposal

To prevent accidental exposure, Bopaho must be stored out of the sight and reach of children.

Due to the active substance's classification as a hazardous drug, disposal of any unused or expired Bopaho must strictly follow the official regulations for hazardous pharmaceutical waste. This necessitates specific handling procedures for the product.